Synta Pharma (SNTA) Presents Encouraging Interim Results from Ganetespib Phase 2

Synta Pharmaceuticals Corp. (Nasdaq: SNTA) announced presentation of results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib, the Company's lead drug candidate, administered as monotherapy for the treatment of metastatic breast cancer. The results are being presented during a poster session at the 2013 San Antonio Breast Cancer Symposium in San Antonio, Texas.

The ENCHANT-1 trial is designed to evaluate the efficacy and safety of ganetespib monotherapy for treatment of HER2+ (Cohort A) or triple-negative (Cohort B) breast cancer (TNBC) patients previously untreated for locally advanced or metastatic disease. A third cohort was recently added to evaluate ganetespib in ER/PR+, HER2- (HER2-negative) patients.

The goal of the window-of-opportunity trial design is to obtain initial evidence of the presence or absence of clinical activity for single-agent ganetespib in patients diagnosed with advanced breast cancer during a 12-week period prior to first-line treatment. Per protocol, all patients enrolled are to receive baseline PET and CT scans, a PET scan at week 3 to assess metabolic response, and subsequent CT scans every 6 weeks to measure best objective response via modified RECIST 1.1 criteria. Continuation of treatment with ganetespib, or the combination of ganetespib and standard-of-care, after the 12-week initial assessment period is at investigator discretion.

Target enrollment is 35 patients in each cohort, with an interim analysis planned at N=15. At the time of interim analysis conducted earlier this year, five patients were enrolled into the HER2+ cohort and 15 patients were enrolled into the TNBC cohort. Of these, four patients in the HER2+ cohort and 11 patients in the triple-negative cohort were evaluable by independent review for objective response, per proctocol.

Of the four patients in the HER2+ cohort evaluable for objective RECIST response by independent review, three patients (75%) achieved an objective response, including one complete radiological response (CR) and two partial responses (PR). One patient (25%) in this cohort achieved stable disease (SD).

Of the 11 patients in the TNBC cohort evaluable for objective RECIST response by independent review, two patients achieved PR (18%) and five patients achieved stable disease (SD, 45%), for a total disease control rate of 64%. As previously reported, one of the responding patients was adjudicated a clinical complete response at week 12 after receiving only three cycles of ganetespib therapy. Her disease was restaged to operable and she underwent a total mastectomy with curative intent. She is now receiving adjuvant chemotherapy.

At the week 3 PET assessment for metabolic response, three of the four patients (75%) evaluable by independent review in the HER2+ cohort achieved a metabolic response. In the triple-negative cohort, four of the 11 patients (36%) evaluable by independent review achieved a week 3 metabolic response.

Consistent with previously reported results, diarrhea, fatigue, and nausea were the most common adverse events associated with ganetespib treatment, and were mostly Grade 1 or 2 in severity.

"The central role that Hsp90 plays in fueling breast cancer growth and metastasis is evidenced by the strong single-agent activity of ganetespib in these difficult-to-treat cancers," said Dr. Neil Spector, Co-Director of Developmental Therapeutics Program, Duke University and an investigator on the trial. "The clinical activity, which includes a complete clinical response as well as a complete radiological response, illustrates the exciting potential for ganetespib in breast cancer, and the rationale for exploring ganetespib in a broader spectrum of disease stages and combinations."

"Results from ENCHANT-1 to date, while early, have demonstrated that ganetespib is clinically active as a single-agent in both HER2+ and triple-negative metastatic breast cancers," said Dr. Iman El-Hariry, Vice President of Clinical Research at Synta. "The results suggest the exciting potential to realize a new category of treatment option for patients with advanced breast cancer, and we are looking forward to vigorously advancing development of ganetespib in breast cancer in order to bring this option to patients."

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.